Segments - by Product Type (Wearable Devices, Conventional Devices, Implantable Devices), by Technology (Electroencephalography (EEG), Magnetoencephalography (MEG), Video Monitoring, Others), by End-User (Hospitals, Neurology Centers, Ambulatory Surgical Centers, Home Care Settings, Others)
This report is updated with the latest market data and insights as of June 2026. Base year: 2025 | Forecast period: 2026-2034
According to our latest research, the global epilepsy monitoring devices market size reached USD 2.24 billion in 2025, demonstrating robust growth driven by technological advancements and increasing prevalence of neurological disorders. The market is projected to expand at a CAGR of 6.8% during the forecast period, reaching an estimated USD 4.1 billion by 2034. This growth is fueled by rising awareness about epilepsy, continuous innovation in monitoring technologies, and a growing emphasis on early and accurate diagnosis for better patient outcomes.
One of the primary growth factors for the epilepsy monitoring devices market is the surging incidence and diagnosis of epilepsy worldwide. As per the World Health Organization, over 50 million people globally are affected by epilepsy, making it one of the most common neurological disorders. The increasing prevalence is not only driving the demand for advanced diagnostic and monitoring solutions but also compelling healthcare systems to invest in specialized epilepsy care. Furthermore, the growing geriatric population, which is more susceptible to neurological disorders, is contributing to the market's expansion. The integration of digital health technologies and remote monitoring capabilities is also enhancing the accessibility of epilepsy care, particularly in underserved regions. The broader landscape of epilepsy treatment and monitoring devices is evolving rapidly, creating significant cross-segment opportunities for manufacturers and healthcare providers alike.
Technological innovation is another significant driver shaping the epilepsy monitoring devices market. The industry has witnessed remarkable progress in device miniaturization, wireless connectivity, and artificial intelligence-powered analytics, all of which are improving the accuracy and usability of monitoring devices. For instance, the development of wearable and implantable devices has revolutionized continuous epilepsy monitoring, enabling real-time data collection and analysis outside traditional clinical settings. These advancements not only facilitate timely intervention but also improve patient compliance and quality of life. Additionally, the integration of cloud-based platforms and telemedicine solutions is streamlining data sharing and collaboration among healthcare providers, further propelling market growth.
The expanding application of epilepsy monitoring devices in home care settings is also contributing to market growth. With the shift towards patient-centric care, there is a growing preference for remote and ambulatory monitoring solutions that allow patients to manage their condition in the comfort of their homes. This trend is particularly pronounced in developed regions with advanced healthcare infrastructure and supportive reimbursement policies. The adoption of home-based monitoring devices is enhancing long-term management of epilepsy, reducing hospital readmissions, and lowering overall healthcare costs. Moreover, the momentum generated by telehealth adoption in previous years has created a durable shift in care delivery expectations, further boosting demand for epilepsy monitoring devices through the 2026-2034 forecast period.
In recent years, the integration of Digital CBT for Epilepsy has emerged as a promising adjunct to traditional epilepsy treatments. Digital Cognitive Behavioral Therapy (CBT) leverages online platforms to deliver therapeutic interventions aimed at managing the psychological aspects of epilepsy. This approach is particularly beneficial for patients experiencing anxiety and depression, which are common comorbidities in epilepsy. By providing accessible and flexible therapy options, Digital CBT empowers patients to take an active role in their mental health management, potentially improving overall treatment adherence and quality of life. As digital health solutions continue to evolve, the incorporation of Digital CBT into epilepsy care protocols is expected to enhance patient outcomes and complement existing monitoring technologies.
Regionally, North America continues to dominate the epilepsy monitoring devices market, accounting for the largest revenue share in 2025. This dominance is attributed to the presence of leading medical device manufacturers, high healthcare expenditure, and widespread adoption of advanced technologies. Europe follows closely, driven by robust healthcare systems and increased funding for neurological research. The Asia Pacific region is expected to witness the fastest growth during the forecast period from 2026 to 2034, supported by rising healthcare investments, growing awareness about epilepsy, and improving access to diagnostic services. The Middle East and Africa and Latin America are also emerging as promising markets, albeit at a slower pace, due to increasing government initiatives and expanding healthcare infrastructure.
The product type segment of the epilepsy monitoring devices market is broadly categorized into wearable devices, conventional devices, and implantable devices. Wearable devices, such as smartwatches and headbands equipped with seizure detection sensors, are gaining significant traction due to their convenience, portability, and ability to provide continuous monitoring. These devices are particularly beneficial for patients with frequent seizures, enabling real-time alerts and facilitating timely medical intervention. The integration of advanced features like wireless connectivity, mobile app synchronization, and cloud-based data storage further enhances their utility and appeal among tech-savvy consumers. As a result, the wearable devices segment is anticipated to witness the highest growth rate during the 2026-2034 forecast period, and the wider category of seizure detection wearables is attracting sustained investment from both established medtech players and emerging digital health startups.
The advent of next-generation seizure detection wearables is transforming the landscape of epilepsy monitoring by offering real-time, continuous surveillance of seizure activity. These wearables, often designed as discreet wristbands or headbands, utilize advanced sensors to detect physiological changes associated with seizures. By providing instant alerts to caregivers and healthcare providers, these devices facilitate timely interventions and enhance patient safety. The convenience and portability of modern wearable monitors make them particularly appealing for individuals with active lifestyles, enabling them to manage their condition with greater autonomy. As technology advances through 2025 and beyond, the accuracy and reliability of these devices are expected to improve significantly, further solidifying their role in comprehensive epilepsy management strategies.
Conventional devices, which include stationary EEG systems and video monitoring setups, remain the gold standard for in-hospital epilepsy diagnosis and monitoring. These devices offer high accuracy and comprehensive data collection, making them indispensable tools in neurology centers and hospitals. Despite their bulkiness and limited mobility, conventional devices continue to hold the largest product segment share at approximately 42% of total market revenue in 2025, particularly in developed regions with advanced healthcare infrastructure. Ongoing improvements in device design, data processing capabilities, and user interfaces are further bolstering their adoption in clinical settings. However, the shift towards ambulatory and home-based monitoring solutions is gradually reshaping the product landscape and encouraging manufacturers to develop lighter, more portable variants of traditional systems.
Implantable devices represent a cutting-edge segment of the epilepsy monitoring devices market, offering continuous, long-term monitoring for patients with refractory epilepsy or those who require detailed seizure characterization. These devices are surgically implanted and can record brain activity over extended periods, providing valuable insights for personalized treatment planning. Recent advancements in biocompatible materials, miniaturization, and wireless data transmission have significantly improved the safety and efficacy of implantable devices. While adoption remains measured due to the invasive nature of the procedure and associated costs, ongoing research and clinical trials are expected to expand their clinical utility and market penetration through the 2026-2034 forecast horizon. The implantable segment holds approximately 19.5% of the global market share as of 2025.
The product type segment is witnessing a trend towards hybrid solutions that combine the strengths of different device categories. For example, some modern systems integrate wearable sensors with cloud-based platforms and AI-powered analytics, offering a comprehensive approach to seizure monitoring and management. This convergence of technologies is creating new opportunities for market players to differentiate their offerings and address unmet clinical needs. As patient preferences shift towards minimally invasive, user-friendly, and cost-effective solutions, manufacturers are investing heavily in R&D to develop next-generation epilepsy monitoring devices that deliver superior performance, seamless connectivity, and measurably better patient outcomes.
| Attributes | Details |
| Report Title | Epilepsy Monitoring Devices Market Research Report 2034 |
| By Product Type | Wearable Devices, Conventional Devices, Implantable Devices |
| By Technology | Electroencephalography (EEG), Magnetoencephalography (MEG), Video Monitoring, Others |
| By End-User | Hospitals, Neurology Centers, Ambulatory Surgical Centers, Home Care Settings, Others |
| Regions Covered | North America, Europe, APAC, Latin America, MEA |
| Base Year | 2025 |
| Historic Data | 2019-2024 |
| Forecast Period | 2026-2034 |
| Number of Pages | 300 |
| Number of Tables & Figures | 257 |
| Customization Available | Yes, the report can be customized as per your need. |
The technology segment of the epilepsy monitoring devices market encompasses Electroencephalography (EEG), Magnetoencephalography (MEG), video monitoring, and other emerging technologies. EEG remains the cornerstone of epilepsy monitoring, providing real-time assessment of electrical activity in the brain. Its non-invasive nature, cost-effectiveness, and widespread availability make it the first-line diagnostic tool for epilepsy. Technological advancements in digital EEG, high-density electrode arrays, and portable systems are enhancing the sensitivity and specificity of seizure detection, driving the adoption of EEG-based devices in both clinical and home settings. Furthermore, the integration of machine learning algorithms is improving the accuracy of automated seizure detection and prediction, reducing the burden on healthcare professionals considerably. The growing field of ambulatory EEG systems is particularly noteworthy, as these portable solutions are enabling continuous monitoring outside hospital walls and dramatically expanding the reach of epilepsy diagnostics.
MEG is an advanced neuroimaging technique that measures the magnetic fields generated by neuronal activity. While less commonly used than EEG, MEG offers superior spatial resolution and is particularly valuable for pre-surgical evaluation and localization of epileptogenic zones. The high cost and limited availability of MEG systems have historically restricted their use to specialized epilepsy centers and research institutions. However, ongoing efforts to develop more affordable and user-friendly MEG devices are expected to broaden their application in clinical practice through the forecast period. The growing emphasis on precision medicine and individualized treatment planning is also driving renewed interest in MEG-based monitoring solutions as of 2025.
Magnetoencephalography is gaining traction as a sophisticated tool for epilepsy monitoring, offering unparalleled insights into brain activity. Unlike traditional EEG, MEG measures the magnetic fields produced by neuronal currents, providing a non-invasive method to pinpoint epileptogenic zones with high spatial resolution. This precision is invaluable for pre-surgical planning, allowing for targeted interventions that minimize the impact on surrounding healthy brain tissue. Despite its high cost and limited availability, ongoing advancements in MEG technology are making it more accessible to a broader range of healthcare facilities. As the demand for precision medicine continues to grow through 2026 and beyond, MEG's role in epilepsy care is expected to expand, offering new avenues for personalized treatment approaches.
Video monitoring is a critical adjunct to EEG and MEG, enabling the simultaneous recording of behavioral and physiological data during seizure episodes. Video-EEG monitoring systems are widely regarded as the gold standard for comprehensive epilepsy evaluation, particularly in patients with complex or atypical seizure presentations. Advances in high-definition video recording, remote monitoring, and cloud-based data storage are enhancing the utility and accessibility of video monitoring systems. These technologies are facilitating the transition from inpatient to ambulatory and home-based monitoring, reducing the need for prolonged hospital stays and improving overall patient comfort and satisfaction.
Other emerging technologies, such as smart sensors, wearable accelerometers, and implantable neurostimulators, are expanding the capabilities of epilepsy monitoring devices. These innovations enable continuous, real-time monitoring of physiological parameters and seizure activity, supporting proactive management and early intervention. The integration of artificial intelligence, big data analytics, and Internet of Things (IoT) platforms is further transforming the technology landscape, enabling personalized care pathways and remote patient management at scale. As the demand for accurate, user-friendly, and cost-effective monitoring solutions grows, technology providers are focusing on developing next-generation devices that leverage these cutting-edge advancements to meet the needs of both clinicians and patients. Parallels can also be drawn with advances in cardiac arrhythmia monitoring, where similar sensor miniaturization and AI-driven analytics breakthroughs are informing the design of next-generation neurological monitoring systems.
The end-user segment of the epilepsy monitoring devices market includes hospitals, neurology centers, ambulatory surgical centers, home care settings, and others. Hospitals remain the largest end-user segment, accounting for a significant share of the market in 2025. The availability of advanced diagnostic infrastructure, skilled healthcare professionals, and comprehensive care pathways make hospitals the preferred setting for initial epilepsy diagnosis, acute management, and pre-surgical evaluation. The adoption of state-of-the-art monitoring devices, such as video-EEG systems and high-density EEG arrays, is particularly high in tertiary care hospitals and academic medical centers, where complex cases are routinely managed.
Neurology centers represent a specialized segment focused on the diagnosis and management of neurological disorders, including epilepsy. These centers are equipped with advanced monitoring technologies and multidisciplinary teams, enabling comprehensive evaluation and personalized care. The growing prevalence of epilepsy and increasing referral rates to neurology specialists are driving the demand for sophisticated monitoring devices in these settings through 2034. Additionally, neurology centers play a pivotal role in clinical research and the adoption of novel technologies, contributing significantly to the overall advancement of the epilepsy monitoring devices market.
Ambulatory surgical centers (ASCs) are emerging as important end-users of epilepsy monitoring devices, particularly for pre-surgical evaluation and post-operative monitoring. The shift towards minimally invasive procedures and outpatient care is driving the adoption of portable and user-friendly monitoring solutions in ASCs. These centers offer a cost-effective alternative to hospital-based care, reducing the burden on healthcare systems and improving patient convenience considerably. The increasing availability of compact, wireless monitoring devices is supporting the expansion of epilepsy care in ambulatory settings and is expected to drive meaningful segment growth through the forecast period.
Home care settings are witnessing rapid growth as patients and healthcare providers increasingly embrace remote monitoring and telehealth solutions. The availability of wearable and wireless monitoring devices is enabling continuous, real-time management of epilepsy in the comfort of patients' homes. This trend is particularly pronounced in regions with advanced digital health infrastructure and supportive reimbursement policies, including the United States, Germany, and Japan. The adoption of home-based monitoring devices is improving long-term disease management, reducing hospital readmissions, and enhancing patient quality of life across all age groups. Other end-users, such as research institutions and rehabilitation centers, also contribute to the market, primarily through the adoption of advanced diagnostic platforms and the validation of emerging technologies.
The epilepsy monitoring devices market presents significant opportunities for growth, driven by ongoing technological innovation and the rising demand for personalized, patient-centric care. The increasing adoption of digital health technologies, such as remote monitoring, telemedicine, and artificial intelligence-powered analytics, is transforming the landscape of epilepsy care. These advancements are enabling early detection, accurate diagnosis, and proactive management of epilepsy, improving patient outcomes and reducing healthcare costs measurably. Market players have the opportunity to capitalize on these trends by developing next-generation devices that offer enhanced functionality, user-friendliness, and interoperability with existing healthcare systems. The convergence of neurological and digital health innovation is creating a fertile ground for differentiated product development and premium pricing strategies.
Another key opportunity lies in the expansion of market reach in emerging economies, where the burden of epilepsy is high but access to specialized care remains limited. Government initiatives to improve healthcare infrastructure, increase awareness about epilepsy, and subsidize the cost of diagnostic devices are creating a conducive environment for market growth in Asia Pacific, Latin America, and parts of Africa. Partnerships with local healthcare providers, investment in training and education programs, and the development of affordable, scalable monitoring solutions can help companies effectively tap into these underserved markets. Additionally, the integration of big data analytics and machine learning algorithms offers significant potential to develop predictive models for seizure risk assessment and truly personalized treatment planning, which represents a major long-term value creation opportunity.
Despite the promising growth prospects, the epilepsy monitoring devices market faces several restraining factors. High costs associated with advanced monitoring devices, particularly implantable and MEG systems, can limit adoption in resource-constrained settings. Reimbursement challenges, regulatory complexities across multiple geographies, and concerns regarding data privacy and cybersecurity also pose significant barriers to market expansion. Furthermore, the invasive nature of certain monitoring procedures and the risk of device-related complications may deter patients and healthcare providers from adopting newer technologies. Addressing these challenges will require concerted efforts from industry stakeholders, regulatory authorities, and healthcare providers to ensure equitable access and optimal utilization of epilepsy monitoring devices across all markets.
North America dominated the epilepsy monitoring devices market in 2025, accounting for a market size of approximately USD 851 million and roughly 38% of global revenue. The region's leadership is attributed to the presence of leading medical device manufacturers, high healthcare expenditure, and widespread adoption of advanced monitoring technologies. The United States, in particular, boasts an extensive network of epilepsy centers and specialized care providers, driving sustained demand for sophisticated monitoring devices. Favorable reimbursement policies, robust research funding, and a proactive regulatory environment further support market growth in North America through the 2026-2034 forecast period.
Europe holds the second-largest share in the global epilepsy monitoring devices market, with a market size of approximately USD 594 million in 2025. The region benefits from well-established healthcare systems, increased funding for neurological research, and rising awareness about epilepsy. Countries such as Germany, the United Kingdom, and France are leading adopters of advanced monitoring technologies, supported by government initiatives to enhance epilepsy care. The market in Europe is expected to grow at a steady CAGR of 6.2% during the forecast period from 2026 to 2034, driven by ongoing investments in healthcare infrastructure and the expansion of telehealth services across the continent.
The Asia Pacific region is poised for the fastest growth, with a market size of approximately USD 437 million in 2025 and a projected CAGR of 8.5% through 2034. Rapid urbanization, increasing healthcare investments, and improving access to diagnostic services are key drivers of market expansion in this region. Countries such as China, India, and Japan are witnessing a surge in demand for epilepsy monitoring devices, fueled by rising awareness, government initiatives, and the growing prevalence of neurological disorders. The broader market for brain monitoring devices is also expanding strongly across Asia Pacific, creating additional infrastructure and distribution pathways that benefit the epilepsy monitoring segment directly. The Middle East and Africa, with a market size of approximately USD 157 million, and Latin America, at approximately USD 202 million, are also emerging as promising markets in 2025, supported by expanding healthcare infrastructure and increasing government-led efforts to address the burden of epilepsy across these regions.
The competitive landscape of the epilepsy monitoring devices market is characterized by the presence of several established players and a growing number of innovative startups. Leading companies are focusing on product innovation, strategic partnerships, and mergers and acquisitions to strengthen their market position and expand their product portfolios. The market is witnessing intense competition as players vie to develop next-generation monitoring solutions that offer enhanced accuracy, user-friendliness, and deep integration with digital health platforms. Continuous investment in research and development, coupled with a strong focus on regulatory compliance and quality assurance, is critical for maintaining a competitive edge in this dynamic and rapidly evolving market.
Key players are leveraging technological advancements to differentiate their offerings and address unmet clinical needs. The integration of artificial intelligence, cloud computing, and wireless connectivity is enabling the development of smart, connected monitoring devices that support remote patient management and truly personalized care pathways. Companies are also investing heavily in the miniaturization of devices, biocompatible materials, and advanced data analytics to improve the safety, efficacy, and usability of their products. Collaborations with healthcare providers, research institutions, and technology partners are facilitating the development and commercialization of innovative solutions tailored to the evolving needs of both patients and clinicians in 2025 and beyond.
The market is also witnessing the entry of new players, particularly in the wearable and home-based monitoring segments. These companies are introducing cost-effective, user-friendly devices that cater to the growing demand for remote and ambulatory monitoring solutions. The increasing focus on direct-to-consumer marketing, patient education, and digital health platform integration is further intensifying competition and driving overall market growth. Established players are responding by expanding their product offerings, enhancing customer support services, and investing in robust post-market surveillance to ensure optimal device performance, regulatory compliance, and long-term patient safety.
Some of the major companies operating in the epilepsy monitoring devices market include Natus Medical Incorporated, Nihon Kohden Corporation, Compumedics Limited, Medtronic plc, Cadwell Industries, Inc., Masimo Corporation, Philips Healthcare, and Empatica Inc. Natus Medical is renowned for its comprehensive portfolio of neurodiagnostic and monitoring solutions, while Nihon Kohden is a global leader in EEG and patient monitoring systems. Compumedics specializes in advanced sleep and neurodiagnostic technologies, and Medtronic is at the forefront of implantable neurostimulation and monitoring devices. Cadwell Industries is known for its innovative EEG and neurophysiology solutions, and Masimo Corporation is a pioneer in non-invasive monitoring technologies. Philips Healthcare offers a wide range of patient monitoring and diagnostic solutions, and Empatica is a leading provider of wearable seizure detection devices. NeuroPace continues to advance closed-loop neurostimulation for refractory epilepsy, while BioSerenity is gaining recognition for its connected garment-based monitoring systems. These companies are continuously investing in R&D, strategic collaborations, and geographic expansion initiatives to maintain their leadership positions and drive future growth through the 2026-2034 forecast period.
The Epilepsy Monitoring Devices market has been segmented on the basis of
The global epilepsy monitoring devices market features a mix of large diversified medtech companies and specialized neurological device firms. Leading players include Natus Medical Incorporated, Nihon Kohden Corporation, Compumedics Limited, Medtronic plc, Cadwell Industries, NeuroPace, Empatica, BioSerenity, Philips Healthcare, GE Healthcare, and Siemens Healthineers. These companies compete on the basis of product innovation, AI integration, clinical evidence generation, and geographic expansion. Smaller specialized players such as Advanced Brain Monitoring, Wearable Sensing, Micromed, and Neurosoft are also gaining traction by targeting niche clinical and ambulatory monitoring applications.
The market faces several meaningful challenges. High device costs, particularly for MEG systems and implantable devices, limit adoption in lower-resource settings. Complex regulatory pathways across different geographies create compliance burdens for manufacturers seeking global market access. Data privacy and cybersecurity concerns are growing as devices become more connected. The invasive nature of implantable monitoring procedures can deter patients, while limited specialist availability in emerging markets constrains adoption. Additionally, inconsistent reimbursement policies across healthcare systems create uncertainty for both providers and manufacturers when investing in advanced monitoring technologies.
Significant opportunities exist across multiple dimensions. The expansion into emerging markets in Asia Pacific, Latin America, and the Middle East and Africa presents considerable untapped potential, where epilepsy burden is high but diagnostic infrastructure remains underdeveloped. The convergence of AI, big data, and wearable technology creates openings for next-generation predictive monitoring platforms. Growing consumer acceptance of digital health tools and favorable policy shifts supporting remote patient monitoring reimbursement are also expanding the addressable market. Partnerships between device manufacturers and digital health companies are unlocking new integrated care models that improve outcomes and reduce costs.
Hospitals are the leading end-user segment, accounting for the largest revenue share in 2025, given their advanced diagnostic infrastructure and role in acute and pre-surgical epilepsy management. Neurology centers are the second major end-user, providing specialized, multidisciplinary care and driving adoption of premium monitoring technologies. Ambulatory surgical centers are growing in importance for outpatient evaluations, while home care settings represent the fastest-growing end-user category as remote and wearable monitoring solutions become more accessible and reimbursable. Research institutions also contribute to demand by validating and adopting novel monitoring technologies.
Electroencephalography (EEG) remains the dominant technology, serving as the first-line diagnostic modality for epilepsy due to its non-invasive nature, cost-effectiveness, and widespread availability. Magnetoencephalography (MEG) offers superior spatial resolution for pre-surgical planning but is confined to specialized centers due to high costs. Video monitoring, especially video-EEG systems, is the gold standard for comprehensive seizure characterization. Emerging technologies include wearable accelerometers, smart biosensors, implantable neurostimulators with monitoring capabilities, and AI-driven analytics platforms that are increasingly being layered onto existing device infrastructure.
Technological advancements are fundamentally reshaping epilepsy monitoring. Artificial intelligence and machine learning algorithms are dramatically improving automated seizure detection accuracy, reducing clinician workload, and enabling predictive risk modeling. Device miniaturization and wireless connectivity are making continuous monitoring viable outside clinical settings. Cloud-based data platforms and IoT integration are streamlining multi-provider care coordination. Improved biocompatible materials are enhancing the safety and longevity of implantable devices, while next-generation wearable sensors are capturing richer physiological datasets for more precise diagnosis.
The market is broadly segmented into three product categories. Wearable devices, including smartwatches, headbands, and wristbands with integrated seizure sensors, are the fastest-growing segment thanks to portability and continuous monitoring capabilities. Conventional devices, such as stationary EEG systems and video-EEG setups, remain the gold standard for in-hospital diagnosis and hold the largest market share at around 42%. Implantable devices offer long-term, continuous brain activity recording for patients with refractory epilepsy and represent the most specialized, high-value segment.
North America holds the largest share of the global market, accounting for approximately 38% of total revenue in 2025, driven by leading device manufacturers, high healthcare expenditure, and advanced epilepsy care networks. Europe follows as the second-largest region at roughly 26.5%, supported by robust healthcare systems and strong neurological research funding. Asia Pacific is the fastest-growing region, projected to expand at a CAGR of approximately 8.5% through 2034, fueled by rising healthcare investments and improving diagnostic access in China, India, and Japan.
Key growth drivers include the rising global burden of epilepsy, which affects more than 50 million people according to the World Health Organization, along with increasing adoption of wearable and remote monitoring technologies. Growing geriatric populations susceptible to neurological disorders, continuous advancements in AI-assisted seizure detection, expanding reimbursement frameworks in developed markets, and the accelerating integration of telehealth platforms are all propelling market expansion through the 2026-2034 forecast period.
The global epilepsy monitoring devices market reached USD 2.24 billion in 2025, the base year of this report. The market is projected to expand at a CAGR of 6.8% during the forecast period from 2026 to 2034, reaching an estimated USD 4.1 billion by 2034. This growth is underpinned by rising epilepsy prevalence worldwide, accelerating adoption of AI-powered monitoring solutions, and a strong shift toward home-based and ambulatory care models.